Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.

Lai, You-Liang; Wang, Kai-Hung; Hsieh, Hsing-Pang; Yen, Wan-Ching

Lai, You-Liang; Wang, Kai-Hung; Hsieh, Hsing-Pang; Yen, Wan-Ching.

Afiliación

Lai YL; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan Town, Maioli County, Taiwan.
Wang KH; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan Town, Maioli County, Taiwan.
Hsieh HP; Department of Medical Research, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Yen WC; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan Town, Maioli County, Taiwan.

J Biomed Sci ; 29(1): 5, 2022 Jan 21.

Article en En | MEDLINE | ID: mdl-35062934

Asunto(s)

Antineoplásicos; Carcinoma Hepatocelular; Neoplasias Hepáticas; Antineoplásicos/farmacología; Antineoplásicos/uso terapéutico; Apoptosis; Carcinoma Hepatocelular/tratamiento farmacológico; Carcinoma Hepatocelular/genética; Línea Celular Tumoral; Proliferación Celular; Resistencia a Antineoplásicos/genética; Células Endoteliales; Humanos; Neoplasias Hepáticas/tratamiento farmacológico; Neoplasias Hepáticas/genética; Sorafenib/farmacología; Ensayos Antitumor por Modelo de Xenoinjerto; Tirosina Quinasa 3 Similar a fms/genética

Palabras clave

Aurora kinases; Hepatocellular carcinoma; Multikinase inhibitors; Sorafenib resistance

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Biomed Sci Asunto de la revista: MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: Taiwán

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google